PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer

Oncogene

Volumn 33, Issue 27, 2014, Pages 3561-3570

  Moon, H ^a   Lee, C S ^b,c   Inder, K L ^a   Sharma, S ^b,c   Choi, E ^a   Black, D M ^a   Le Cao K A ^a   Winterford, C ^a   Coward, J I ^d   Ling, M T ^e   Craik, D J ^a   Parton, R G ^a   Russell, P J ^e   Hill, M M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

^d TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

caveolae; caveolin 1; cavin 1; prostate cancer; PTRF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANDROGEN RECEPTOR; CAVEOLIN 1; CAVIN 1; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CANCER CELL; CANCER GROWTH; CAVEOLA; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

MUS;

ACTINS; AGED; ANIMALS; CAVEOLIN 1; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE MICRODOMAINS; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RNA-BINDING PROTEINS;

EID: 84906923001     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.315     Document Type: Article

References (49)

1. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23: 9389-9404.
2. Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC et al. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol 2011; 43: 1318-1329.
3. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68: 731-739.
4. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
5. Gumulec J, Sochor J, Hlavna M, Sztalmachova M, Krizkova S, Babula P et al. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep 2012; 27: 831-841.
6. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9: 3653-3659.
7. Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE et al. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma 2012; 31: 77-86.
8. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-194.
9. Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, Nixon SJ et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008; 132: 113-124.
10. Aung CS, Hill MM, Bastiani M, Parton RG, Parat MO. PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metallopro-tease 9. Eur J Cell Biol 2011; 90: 136-142.
11. Hill MM, Daud NH, Aung CS, Loo D, Martin S, Murphy S et al. Co-regulation of cell polarization and migration by caveolar proteins PTRF/Cavin-1 and caveolin-1. PLoS One 2012; 7: e43041.
12. Inder KL, Zheng YZ, Davis MJ, Moon H, Loo D, Nguyen H et al. Expression of PTRF in PC-3 cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways. Mol Cell Proteomics 2012; 11(M111): 012245.
13. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin, and poly-merase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 2010; 70: 1609-1621.
14. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8: 2420-2424.
15. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4: 1873-1880.
16. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-5723.
17. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67: 614-622.
18. Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, Lee TK et al. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer 2011; 128: 2182-2191.
19. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012; 360: 52-58.
20. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med 2012; 90: 1343-1355.
21. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66: 3087-3095.
22. Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2013; 31: 669-676.
23. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara Jr PN, Van Veldhuizen Jr PJ et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (sil-tuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pre-treated patients with castration-resistant prostate cancer. Clin Cancer Res 2010; 16: 3028-3034.
24. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4: 1062-1064.
25. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70: 6945-6956.
26. Hugo HJ, Lebret S, Tomaskovic-Crook E, Ahmed N, Blick T, Newgreen DF et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron 2012; 5: 83-93.
27. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 9087-9095.
28. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
29. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A et al. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 2002; 168: 1589-1596.
30. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated trans-activation. J Biol Chem 2001; 276: 13442-13451.
31. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009; 7: 1781-1791.
32. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-146.
33. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38: 199-207.
34. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12: 33-40.
35. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008; 27: 715-735.
36. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12: 4872-4875.
37. Hansen CG, Bright NA, Howard G, Nichols BJ. SDPR induces membrane curvature and functions in the formation of caveolae. Nat Cell Biol 2009; 11: 807-814.
38. McMahon KA, Zajicek H, Li WP, Peyton MJ, Minna JD, Hernandez VJ et al. SRBC/ cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J 2009; 28: 1001-1015.
39. Bastiani M, Liu L, Hill MM, Jedrychowski MP, Nixon SJ, Lo HP et al. MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. J Cell Biol 2009; 185: 1259-1273.
40. Bai L, Deng X, Li Q, Wang M, An W, Deli A et al. Down-regulation of the cavin family proteins in breast cancer. J Cell Biochem 2012; 113: 322-328.
41. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG et al. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 2008; 99: 1326-1333.
42. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009; 4: 255-264.
43. Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res 2001; 61: 7943-7949.
44. Aboulaich N, Vainonen JP, Stralfors P, Vener AV. Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes. Biochem J 2004; 383: 237-248.
45. Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146: 148-163.
46. Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 2009; 61: 961-970.
47. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
48. Skalamera D, Ranall MV, Wilson BM, Leo P, Purdon AS, Hyde C et al. A high-throughput platform for lentiviral overexpression screening of the human ORFeome. PLoS One 2011; 6: e20057.
49. Skalamera D, Dahmer M, Purdon AS, Wilson BM, Ranall MV, Blumenthal A et al. Generation of a genome scale lentiviral vector library for EF1alpha promoter-driven expression of human ORFs and identification of human genes affecting viral titer. PLoS One 2012; 7: e51733.